Work

Abstract CT020: Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-ct020

Authors: Marjorie G. Zauderer, David M. Hyman, Evan W. Alley, Johanna C. Bendell, Silvia Novello, Todd M. Bauer, Axel-Rainer Hanauske, Anna M. Szpurka, Suhyun Kang, Anindya Chatterjee, Volker Wacheck, Patrick Brueck, Anna M. Varghese

Institutions: Memorial Sloan Kettering Cancer Center, University of Pennsylvania, Sarah Cannon, Tennessee Oncology, University of Turin, Eli Lilly (Germany), Eli Lilly (United States), TU Wien

Language: English

Topic: Occupational and environmental lung diseases

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2887705420

Cites:

Cited by:

Related to: 10